Nanomedicine News

RSS

Researchers Open and Close Nanovesicles Using a Magnet

Chemists and physicists of Radboud University managed to open and close nanovesicles using a magnet. This process is repeatable and can be controlled remotely, allowing targeted drug transport in the body, for example.

26 Sep 2014

Swissmedic Approves Celgene’s ABRAXANE for Treatment of Metastatic Pancreatic and Breast Cancers

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation, today announced that Swissmedic, the regulatory authority for Switzerland, has granted approval for ABRAXANE® (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) as a treatment for metastatic pancreatic cancer (in combination with gemcitabine), and as a treatment for metastatic breast cancer.

25 Sep 2014

Liquidia to Present Unique Nanofabrication of Vaccine Formulations

Liquidia Technologies today announced it will highlight the rapid antigen and adjuvant formulation capabilities of its PRINT®(Particle Replication In Non-Wetting Templates) technology for the development of novel vaccines at the 4th International Conference on Vaccines and Vaccination, being held September 24-26, in Valencia, Spain.

From Liquidia Technologies, Inc. 24 Sep 2014

Cancer-Immune Cyberwar Nanocarriers

Research by Rice University scientists who are fighting a cyberwar against cancer finds that the immune system may be a clinician's most powerful ally.

24 Sep 2014

Novavax Reports Positive Data from Phase 1/2 Clinical Trial of H7N9 VLP with Matrix-M

Novavax, Inc. a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1/2 clinical trial of its H7N9 Avian Influenza VLP Vaccine Candidate (H7N9 VLP) with proprietary adjuvant Matrix-M™.

From Novavax Inc. 24 Sep 2014

Tekmira to Provide RNAi Based Investigational Therapeutic for Clinical Studies in West Africa

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today reported that it is collaborating with an international consortium to provide an RNAi based investigational therapeutic for expedited clinical studies in West Africa.

24 Sep 2014

FDA Authorizes Tekmira to Provide Treatment to Subjects with Confirmed/Suspected Ebola Virus Infections

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today announced that the FDA has authorized Tekmira to provide TKM-Ebola for treatment under expanded access protocols to subjects with confirmed or suspected Ebola virus infections.

23 Sep 2014

New Tumor-Microenvironment-On-Chip Device Tests Effectiveness of Nanoparticles

Researchers have developed a chip capable of simulating a tumor's "microenvironment" and plan to use the new system to test the effectiveness of nanoparticles and drugs that target cancer.

23 Sep 2014

NANOBIOTIX Opens First US Office in Boston, Massachusetts

NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the opening of its first US office in Boston, Massachusetts, the global center for life sciences.

From Nanobiotix 23 Sep 2014

Magnetothermal Multiplexing of Nanomaterials Holds Promise for Targeted Drug Delivery

Magnetic nanoparticles don’t have to be "one size fits all." Instead, individual magnetic nanoparticles can be tailored in an array of differing sizes and compositions to allow for heating them separately by varying the frequency and amplitude of an external alternating magnetic field, MIT graduate student Michael G. Christiansen and colleagues show in a recent Applied Physics Letters paper.

From Massachusetts Institute of Technology 19 Sep 2014

Nanomedicine News

Researchers Open and Close Nanovesicles Using a Magnet

Swissmedic Approves Celgene’s ABRAXANE for Treatment of Metastatic Pancreatic and Breast Cancers

Liquidia to Present Unique Nanofabrication of Vaccine Formulations

Cancer-Immune Cyberwar Nanocarriers

Novavax Reports Positive Data from Phase 1/2 Clinical Trial of H7N9 VLP with Matrix-M

Tekmira to Provide RNAi Based Investigational Therapeutic for Clinical Studies in West Africa

FDA Authorizes Tekmira to Provide Treatment to Subjects with Confirmed/Suspected Ebola Virus Infections

New Tumor-Microenvironment-On-Chip Device Tests Effectiveness of Nanoparticles

NANOBIOTIX Opens First US Office in Boston, Massachusetts

Magnetothermal Multiplexing of Nanomaterials Holds Promise for Targeted Drug Delivery

Combining Nanofluids and Turbulators for Sustainable Energy

Enhancing Material Properties through Nanotube Encapsulation

Sustainable Carbon Nanomaterial Gii Set to Transform Energy Storage in Internet of Things Devices

Brain-Inspired Nano-Tech Promises New Era for Electronics

Breakthrough in 2D Material Growth Opens Doors to Cleaner Energy and Next-Generation Technology

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials